Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
By
Helena de Castro e Gloria
Laura Jesuíno Nogueira
Patrícia Bencke Grudzinski
Paola Victória da Costa Ghignatti
Temenouga Nikolova Guecheva
Natalia Motta Leguisamo
Jenifer Saffi
July 1, 2026
Clinical Scorecard: Correction: Enhanced Cytotoxic Effects of 5-Fluorouracil by Olaparib in Colorectal Cancer Cells with Mismatch Repair Deficiency
At a Glance
Category Detail
Condition Colorectal Cancer with Mismatch Repair Deficiency Key Mechanisms Enhanced cytotoxic effects of 5-Fluorouracil by Olaparib Target Population Patients with colorectal cancer exhibiting mismatch repair deficiency Care Setting Oncology research and treatment
Key Highlights
Correction of image duplication in published article Quantitative analysis performed on original sample slides Replacement of image does not affect reported results Focus on cytotoxic effects of combination therapy Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with mismatch repair deficient colorectal cancer
Combination of 5-Fluorouracil and Olaparib
Clinical Best Practices
Related Resources & Content
